Efficacy of montelukast, a leukotriene receptor antagonist, for the treatment of dysmenorrhea: A prospective, double-blind, randomized, placebo-controlled study

2010 ◽  
Vol 148 (2) ◽  
pp. 195-198 ◽  
Author(s):  
Hiroyuki Fujiwara ◽  
Ryo Konno ◽  
Sachiho Netsu ◽  
Kohei Odagiri ◽  
Akiyo Taneichi ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Controlled Study ◽  
Leukotriene Receptor Antagonist ◽  
Double Blind ◽  
Leukotriene Receptor

Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis-a randomized placebo-controlled study

2009 ◽  
Vol 44 (11) ◽  
pp. 1085-1092 ◽  
Author(s):  
Albert M. Li ◽  
Victor J. Abdullah ◽  
Chui S. Tsen ◽  
Chun T. Au ◽  
Hugh S. Lam ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Receptor Antagonist ◽  
Controlled Study ◽  
Leukotriene Receptor Antagonist ◽  
Leukotriene Receptor

The Effects of Montelukast on Intradermal Wheal and Flare

2003 ◽  
Vol 129 (3) ◽  
pp. 199-203 ◽  
Author(s):  
Samuel L. Hill ◽  
John H. Krouse
Keyword(s):  
Skin Testing ◽  
Controlled Study ◽  
Significant Suppression ◽  
Leukotriene Receptor Antagonist ◽  
Double Blind ◽  
Significant Difference ◽  
Leukotriene Receptor ◽  
Wheal And Flare ◽  
University Setting ◽  
Wheal Size

OBJECTIVE: We sought to determine the effect of montelukast, a leukotriene receptor antagonist, on intradermal skin testing. STUDY DESIGN AND SETTING: We conducted a prospective, randomized, double-blind, placebo-controlled study in a university setting. METHODS: After a 1 -week washout of allergy pharmacotherapy, intradermal skin testing was performed on 23 atopic subjects. Whealing size was measured 20 minutes after injection. Subjects then began a 1 -week regimen of daily loratadine, montelukast, or placebo. At 1 week, subjects again underwent intradermal skin testing. The change in wheal size was then calculated from baseline. RESULTS: A significant difference ( P < 0.05) between the montelukast and loratadine groups in suppression of intradermal whealing at 1 week was observed. No significant difference was noted between the montelukast and placebo subjects. CONCLUSIONS: Montelukast demonstrated no significant suppression of skin whealing after antigen challenge over placebo. SIGNIFICANCE: Montelukast does not need to be discontinued before intradermal allergy testing.

Sign in / Sign up

Export Citation Format

Share Document